27:"/_next/static/immutable/chunks/1caiys5hgvzzo.js" 28:"/_next/static/immutable/chunks/1qmpoydqg-n72.js" 29:I[3292,["$4","$5","$6","$9","$a","$13","$27","$28"],"default"] 2d:I[27201,["$4","$5","$6"],"IconMark"] 2a:T55e,Peritoneal metastases (PM) are a common manifestation of gastrointestinal cancer. The prognosis of patients with PM is particularly poor, and response to systemic chemotherapy is worse compared to parenchymal metastatic cancer in the liver or lungs. In addition, patients with PM frequently develop debilitating symptoms such as intractable ascites, bowel obstruction, or ureteric obstruction, resulting in a severely compromised quality of life. In selected patients with widespread PM, pressurized intraperitoneal aerosol chemotherapy (PIPAC) holds considerable promise. Briefly, PIPAC combines laparoscopy with intraperitoneal (IP) administration of chemotherapy as an aerosol, which is generated by a nebulizer. The pharmacokinetic (PK) and clinical advantages of PIPAC may be further enhanced by using nanosized anticancer drugs. Nal-IRI (Onivyde) is a nanoliposomal formulation of irinotecan (Camptothecin-11 (CPT-11)), with a markedly superior efficacy when compared with free CPT-11 in human breast and colon cancer xenograft models. This is a phase I clinical study with aerosolized IP Nal-IRI in patients with PM from GI cancer. In this phase I study, dose escalation will be combined with pharmacokinetic/pharmacodynamic modelling which incorporates, in addition to plasma, tumour tissue, and peritoneal drug concentrations, biomarkers of toxicity and efficacy.2b:T700,Inclusion Criteria: * Biopsy proven cancer of the pancreas, gallbladder or biliary tract, stomach, small bowel, colon, rectum, or appendix with extensive or irresectable peritoneal carcinomatosis * Estimated life expectancy \> 6 months; \> 3 months if primary cancer is pancreatic * Age ≥ 18 years * Adequate performance status (Karnofsky index \> 60% and WHO performance status \< 2) * Written informed consent obtained prior any act of the research Exclusion Criteria: * Concomitant systemic (IV) treatment with irinotecan (either as monotherapy or as part of a combination regimen such as FOLFIRI, CAPIRI, or FOLFOXIRI) * Pregnancy or breastfeeding during the clinical study * Patients of childbearing age unable or unwilling to provide effective contraception during the study and until the end of relevant exposure (extended by 30 days (female participants) or 120 days (male participants) since the IMP is genotoxic). * Known allergy or intolerance to irinotecan * Significant amount of ascites detectable (exceeding 3l in volume) * Intestinal or urinary tract obstruction * Extensive hepatic and/or extra-abdominal metastatic disease * Impaired renal function (serum creatinine \> 1.5 mg/dl or calculated GFR (CKD-EPI) \< 60 mL/min/1.73 m² * Impaired liver function (serum total bilirubin \> 1.5 mg/dl, except for known Gilbert's disease) * Platelet count \< 100.000/µl * Hemoglobin \< 9g/dl * Neutrophil granulocytes \< 1.500/ml * Patients known to use: * CYP3A4 inducers (rifampin, phenytoin, carbamazepine, rifabutin, rifapentine, phenobarbital, St John's wort) * inhibitors of CYP3A4 (clarithromycin, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telaprevir, voriconazole) or UGT1A1 (atazanavir, gemfibrozil, indinavir, regorafenib)2c:T687,Les métastases péritonéales (MP) sont une manifestation fréquente du cancer gastro-intestinal. Le pronostic des patients atteints de MP est particulièrement sombre et la réponse à la chimiothérapie systémique est moins bonne que pour les métastases parenchymateuses hépatiques ou pulmonaires. De plus, les patients atteints de MP développent fréquemment des symptômes invalidants tels qu'une ascite réfractaire, une occlusion intestinale ou urétérale, entraînant une altération sévère de la qualité de vie. Chez certains patients atteints de MP étendue, la chimiothérapie par aérosol intrapéritonéal pressurisé (PIPAC) est très prometteuse. En résumé, la PIPAC associe la laparoscopie à l'administration intrapéritonéale (IP) de chimiothérapie sous forme d'aérosol, générée par un nébuliseur. Les avantages pharmacocinétiques (PK) et cliniques de la PIPAC pourraient être encore améliorés par l'utilisation de médicaments anticancéreux de taille nanométrique. Le Nal-IRI (Onivyde) est une formulation nanoliposomale d'irinotécan (camptothécine-11 [CPT-11]), dont l'efficacité est nettement supérieure à celle du CPT-11 libre dans des modèles de xénogreffes de cancer du sein et du côlon humains. Il s'agit d'une étude clinique de phase I portant sur le Nal-IRI IP en aérosol chez des patients atteints de MP d'un cancer gastro-intestinal. Dans cette étude de phase I, l'augmentation de la dose sera combinée à une modélisation pharmacocinétique/pharmacodynamique intégrant, outre les concentrations plasmatiques, tissu tumoral et péritonéales du médicament, des biomarqueurs de toxicité et d'efficacité.19:[["$","script",null,{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"MedicalStudy\",\"name\":\"PIPAC-NAL-IRI\",\"url\":\"https://app.klineo.com/fr/trial/NCT05277766\",\"description\":\"Irinotécan nanoliposomal en aérosol intrapéritonéal (Nal-IRI) dans la carcinose péritonéale due à un cancer gastro-intestinal L'étude PIPAC NAL-IRI est conçue pour examiner la dose maximale tolérée d'irinotécan nanoliposomal (Nal-IRI, Onivyde) administrée avec une chimiothérapie par aérosol intrapér\",\"identifier\":[{\"@type\":\"PropertyValue\",\"propertyID\":\"ClinicalTrials.gov\",\"value\":\"NCT05277766\"},{\"@type\":\"PropertyValue\",\"propertyID\":\"EU CT\",\"value\":\"2023-509135-17-00\"}],\"sponsor\":[{\"@type\":\"Organization\",\"name\":\"University Ghent\"},{\"@type\":\"Organization\",\"name\":\"Kom Op Tegen Kanker\"},{\"@type\":\"Organization\",\"name\":\"University Hospital, Ghent\"}],\"healthCondition\":[{\"@type\":\"MedicalCondition\",\"name\":\"Toutes histologies\"}],\"phase\":\"Phase 1\"}"}}],["$","$L29",null,{"trial":{"id":"24299ded-ec73-4906-b907-76d9aac7cb97","nctId":"NCT05277766","euctId":"2023-509135-17-00","aactOfficialTitle":"Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer: a Phase I Study","aactBriefSummary":"The PIPAC NAL-IRI study is designed to examine the maximal tolerated dose of nanoliposomal irinotecan (Nal-IRI, Onivyde) administered with repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC), in a monocentric, phase I trial.","aactDescription":"$2a","aactCriteria":"$2b","aactAcronym":"PIPAC-NAL-IRI","aactBriefTitle":"Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer","trialCriterias":[{"id":"b7ce4f43-2000-46c6-a209-05ed5365e9c2","type":"EXCLUSION","category":null,"shortDescription":"* Traitement systémique concomitant (IV) par l'irinotécan (soit en monothérapie, soit dans le cadre d'un traitement combiné tel que FOLFIRI, CAPIRI ou FOLFOXIRI)","description":"* Traitement systémique concomitant (IV) par l'irinotécan (soit en monothérapie, soit dans le cadre d'un traitement combiné tel que FOLFIRI, CAPIRI ou FOLFOXIRI)","isImportant":true},{"id":"1993c9dc-903f-4d7d-81f9-f6889ed14c02","type":"INCLUSION","category":null,"shortDescription":"* Cancer du pancréas, de la vésicule biliaire ou des voies biliaires, de l'estomac, de l'intestin grêle, du côlon, du rectum ou de l'appendice prouvé par biopsie avec carcinose péritonéale étendue ou irrésécable","description":"* Cancer du pancréas, de la vésicule biliaire ou des voies biliaires, de l'estomac, de l'intestin grêle, du côlon, du rectum ou de l'appendice prouvé par biopsie avec carcinose péritonéale étendue ou irrésécable","isImportant":true},{"id":"8aeffa94-e134-4f96-a7cb-e5d65c01f454","type":"INCLUSION","category":null,"shortDescription":"","description":"* Espérance de vie estimée \\> 6 mois ; \\> 3 mois si le cancer primaire est pancréatique","isImportant":false},{"id":"1bc950e1-39fa-447a-897f-c21de21656db","type":"EXCLUSION","category":null,"shortDescription":"","description":"* Grossesse ou allaitement pendant l'étude clinique","isImportant":false},{"id":"5663fa02-28f8-4ccd-9d28-151def3a9641","type":"INCLUSION","category":null,"shortDescription":"","description":"* Âge ≥ 18 ans","isImportant":false},{"id":"a2572a94-21c9-4a02-96de-36a34caf3600","type":"EXCLUSION","category":null,"shortDescription":"","description":"* Patients en âge de procréer incapables ou refusant de fournir une contraception efficace pendant l'étude et jusqu'à la fin de l'exposition pertinente (prolongée de 30 jours (participantes féminines) ou de 120 jours (participants masculins) puisque l'IMP est génotoxique).","isImportant":false},{"id":"dbb0e959-b6ff-4d79-a22f-efcd751249f3","type":"INCLUSION","category":null,"shortDescription":"","description":"* Statut de performance adéquat (indice de Karnofsky \\> 60% et statut de performance de l'OMS \\< 2)","isImportant":false},{"id":"3f8ba83d-25c8-42bc-bee7-cef69a3ba6b6","type":"EXCLUSION","category":null,"shortDescription":"","description":"* Allergie ou intolérance connue à l'irinotécan","isImportant":false},{"id":"93ad2c04-f016-43b1-8c22-dfd181355de8","type":"EXCLUSION","category":null,"shortDescription":"","description":"* Quantité importante d'ascite détectable (volume supérieur à 3 l)","isImportant":false},{"id":"2dbb5d0b-63cb-4bd2-87ac-4afc063ec055","type":"INCLUSION","category":null,"shortDescription":"","description":"* Consentement éclairé écrit obtenu avant tout acte de recherche","isImportant":false},{"id":"db5deb4d-e726-4455-9439-cdc558b17b94","type":"EXCLUSION","category":null,"shortDescription":"","description":"* Obstruction intestinale ou urinaire","isImportant":false},{"id":"39ed24ca-f695-47c1-a537-e8dac2f5db94","type":"EXCLUSION","category":null,"shortDescription":"","description":"* Maladie métastatique hépatique étendue et/ou extra-abdominale","isImportant":false},{"id":"39492d01-a08f-4d89-99b6-203067a12291","type":"EXCLUSION","category":null,"shortDescription":"","description":"* Fonction rénale altérée (créatinine sérique \\> 1,5 mg/dl ou DFG calculé (CKD-EPI) \\< 60 mL/min/1,73 m²","isImportant":false},{"id":"b8823084-f480-4bf0-9847-eb2c24ec66ea","type":"EXCLUSION","category":null,"shortDescription":"","description":"* Insuffisance hépatique (bilirubine totale sérique > 1,5 mg/dl, sauf en cas de maladie de Gilbert connue)","isImportant":false},{"id":"fa990296-7c18-491a-8620-4b090c31d04c","type":"EXCLUSION","category":null,"shortDescription":"","description":"* Numération plaquettaire \\< 100 000/µl","isImportant":false},{"id":"cbf8e6ac-ed15-4c46-a6ea-317bfd57402f","type":"EXCLUSION","category":null,"shortDescription":"","description":"* Hémoglobine \\< 9g/dl","isImportant":false},{"id":"38ee173f-7f09-4942-8fb0-2dd44bf16bb6","type":"EXCLUSION","category":null,"shortDescription":"","description":"* Granulocytes neutrophiles \\< 1.500/ml","isImportant":false},{"id":"e59c120f-26ce-471c-b886-c6f0c6a0c575","type":"EXCLUSION","category":null,"shortDescription":"","description":"* Inducteurs du CYP3A4 (rifampicine, phénytoïne, carbamazépine, rifabutine, rifapentine, phénobarbital, millepertuis)","isImportant":false},{"id":"b5d354a8-e4eb-4636-b120-10ebc5f3df91","type":"EXCLUSION","category":null,"shortDescription":"","description":"* inhibiteurs du CYP3A4 (clarithromycine, indinavir, itraconazole, lopinavir, néfazodone, nelfinavir, ritonavir, saquinavir, télaprévir, voriconazole) ou de l'UGT1A1 (atazanavir, gemfibrozil, indinavir, régorafénib)","isImportant":false}],"trialMetadata":{"acronym":"PIPAC-NAL-IRI","id":"925e5781-ff44-4f99-8953-f4b6daabcf8e","studyType":"INTERVENTIONAL_THERAPEUTIC","areCohortsConfidential":false,"briefTitle":"Irinotécan nanoliposomal en aérosol intrapéritonéal (Nal-IRI) dans la carcinose péritonéale due à un cancer gastro-intestinal","officialTitle":"Irinotécan nanoliposomal en aérosol intrapéritonéal (Nal-IRI) dans la carcinose péritonéale due à un cancer gastro-intestinal : une étude de phase I","klineoTitle":"Irinotécan nanoliposomal en aérosol intrapéritonéal (Nal-IRI) dans la carcinose péritonéale due à un cancer gastro-intestinal : une étude de phase I","briefSummary":"L'étude PIPAC NAL-IRI est conçue pour examiner la dose maximale tolérée d'irinotécan nanoliposomal (Nal-IRI, Onivyde) administrée avec une chimiothérapie par aérosol intrapéritonéal pressurisé répété (PIPAC), dans un essai monocentrique de phase I.","description":"$2c","partnerDescriptionUrl":null,"maximumAge":null,"maximumLines":null,"minimumAge":18,"minimumLines":1,"brainJustification":"","isLlmMatchingVisible":false,"sponsors":[{"name":"University Ghent"},{"name":"Kom Op Tegen Kanker"},{"name":"University Hospital, Ghent"}],"medicalMetadata":{"id":"e9748e70-0a33-437b-89d6-913c409ee028","phase":"ONE","oms":null,"recistMeasurable":null,"brainMetastasis":"NO","situations":["METASTATIC"],"histologies":[{"id":"483180e5-b7ca-44b9-a64d-d076ffb278cd","name":"Toutes histologies","slug":"All histologies"}],"biomarkerAlterations":[{"id":"ba146068-348a-458a-ae5a-db680365f7b4","name":"Non ciblé","slug":"Non ciblé"}],"organs":[{"id":"c20c3e8b-a9f4-4544-94b2-bf33f827099a","name":"Appendice","slug":"Appendix","availabilityStatus":"NATIONAL"},{"id":"a1a48b7c-8a7c-4db8-92f3-3caf450fc27c","name":"Estomac","slug":"Gastric","availabilityStatus":"NATIONAL"},{"id":"bb7be128-2146-4953-b4c5-c1789a5ec52a","name":"Intestin","slug":"Small bowel","availabilityStatus":"NATIONAL"},{"id":"e88e1a30-6607-43cb-8071-25e3e4b205fe","name":"Pancréas","slug":"Pancreas","availabilityStatus":"NATIONAL"},{"id":"637b9ce7-49bd-4da1-943b-63b9a4efa9be","name":"Péritoine","slug":"Peritoneum","availabilityStatus":"NATIONAL"},{"id":"c848dc1d-9fd8-41d2-899b-62ecfb6f9c24","name":"Rectum","slug":"Rectum","availabilityStatus":"NATIONAL"},{"id":"ba1cf127-4ae9-4e7b-81df-99983e13238f","name":"Voies biliaires","slug":"Bile duct","availabilityStatus":"NATIONAL"}],"specialities":[{"id":"48c78eab-0416-4ced-b901-9de7da518478","name":"Digestif","slug":"Gastrointestinal cancer","availabilityStatus":"NATIONAL"}]}},"interventions":[{"id":"b2976b83-6a71-4fc1-b58a-2fff612cf5f7","name":"PIPAC avec Nal-IRI","description":"L'irinotécan nanoliposomal (Nal-IRI, Onivyde) sera administré par voie intrapéritonéale selon la technique PIPAC. La dose administrée sera progressive, allant de 30 à 90 mg/m². Le PIPAC sera réalisé toutes les 4 à 6 semaines pendant 3 cycles.","targets":[],"type":"DRUG","treatmentFamily":{"id":"78fe594b-e045-40fa-a268-cd7fdcc52dfb","name":"Chimiothérapie","slug":"Chemotherapy"},"moleculeStructure":{"id":"899f432c-995c-465e-86b8-75ca91968726","name":"Chimiothérapie","slug":"Chemotherapy"},"mechanismOfAction":{"id":"06686a02-423a-4ab1-b2d4-4207de24df86","name":"Chimiothérapie (cytotoxicité)","slug":"Chemotherapy (cytotoxicity)"},"routeOfAdministration":{"name":"Autre"}}],"cohorts":[{"id":"c2df321b-db64-4491-a4b0-fb215062aedd","name":"EXPÉRIMENTAL : Nal-IRI (Onivyde) - 30 mg/m²","maximumLines":null,"minimumLines":1,"allBiomarkerAlterationRequired":true,"medicalMetadata":{"id":"769d138e-4184-4975-a33f-ef7d7f04e3e5","phase":"ONE","oms":null,"recistMeasurable":null,"brainMetastasis":"NO","situations":["METASTATIC"],"organs":[{"id":"c20c3e8b-a9f4-4544-94b2-bf33f827099a","name":"Appendice","slug":"Appendix","availabilityStatus":"NATIONAL"},{"id":"a1a48b7c-8a7c-4db8-92f3-3caf450fc27c","name":"Estomac","slug":"Gastric","availabilityStatus":"NATIONAL"},{"id":"bb7be128-2146-4953-b4c5-c1789a5ec52a","name":"Intestin","slug":"Small bowel","availabilityStatus":"NATIONAL"},{"id":"e88e1a30-6607-43cb-8071-25e3e4b205fe","name":"Pancréas","slug":"Pancreas","availabilityStatus":"NATIONAL"},{"id":"637b9ce7-49bd-4da1-943b-63b9a4efa9be","name":"Péritoine","slug":"Peritoneum","availabilityStatus":"NATIONAL"},{"id":"c848dc1d-9fd8-41d2-899b-62ecfb6f9c24","name":"Rectum","slug":"Rectum","availabilityStatus":"NATIONAL"},{"id":"ba1cf127-4ae9-4e7b-81df-99983e13238f","name":"Voies biliaires","slug":"Bile duct","availabilityStatus":"NATIONAL"}],"histologies":[{"id":"483180e5-b7ca-44b9-a64d-d076ffb278cd","name":"Toutes histologies","slug":"All histologies"}],"specialities":[{"id":"48c78eab-0416-4ced-b901-9de7da518478","name":"Digestif","slug":"Gastrointestinal cancer","availabilityStatus":"NATIONAL"}],"biomarkerAlterations":[{"id":"ba146068-348a-458a-ae5a-db680365f7b4","name":"Non ciblé","slug":"Non ciblé"}]}},{"id":"cb85569c-10e1-483c-85a2-660aaf0c5ebc","name":"EXPÉRIMENTAL : Nal-IRI (Onivyde) - 45 mg/m²","maximumLines":null,"minimumLines":1,"allBiomarkerAlterationRequired":true,"medicalMetadata":{"id":"341dd204-d29a-4777-a4c3-3a0bda61578d","phase":"ONE","oms":null,"recistMeasurable":null,"brainMetastasis":"NO","situations":["METASTATIC"],"organs":[{"id":"c20c3e8b-a9f4-4544-94b2-bf33f827099a","name":"Appendice","slug":"Appendix","availabilityStatus":"NATIONAL"},{"id":"a1a48b7c-8a7c-4db8-92f3-3caf450fc27c","name":"Estomac","slug":"Gastric","availabilityStatus":"NATIONAL"},{"id":"bb7be128-2146-4953-b4c5-c1789a5ec52a","name":"Intestin","slug":"Small bowel","availabilityStatus":"NATIONAL"},{"id":"e88e1a30-6607-43cb-8071-25e3e4b205fe","name":"Pancréas","slug":"Pancreas","availabilityStatus":"NATIONAL"},{"id":"637b9ce7-49bd-4da1-943b-63b9a4efa9be","name":"Péritoine","slug":"Peritoneum","availabilityStatus":"NATIONAL"},{"id":"c848dc1d-9fd8-41d2-899b-62ecfb6f9c24","name":"Rectum","slug":"Rectum","availabilityStatus":"NATIONAL"},{"id":"ba1cf127-4ae9-4e7b-81df-99983e13238f","name":"Voies biliaires","slug":"Bile duct","availabilityStatus":"NATIONAL"}],"histologies":[{"id":"483180e5-b7ca-44b9-a64d-d076ffb278cd","name":"Toutes histologies","slug":"All histologies"}],"specialities":[{"id":"48c78eab-0416-4ced-b901-9de7da518478","name":"Digestif","slug":"Gastrointestinal cancer","availabilityStatus":"NATIONAL"}],"biomarkerAlterations":[{"id":"ba146068-348a-458a-ae5a-db680365f7b4","name":"Non ciblé","slug":"Non ciblé"}]}},{"id":"458e2492-92e1-4b21-a75c-bbb799c14f52","name":"EXPÉRIMENTAL : Nal-IRI (Onivyde) - 60 mg/m²","maximumLines":null,"minimumLines":1,"allBiomarkerAlterationRequired":true,"medicalMetadata":{"id":"8a9754e6-2c97-492e-945c-5465c04690fa","phase":"ONE","oms":null,"recistMeasurable":null,"brainMetastasis":"NO","situations":["METASTATIC"],"organs":[{"id":"c20c3e8b-a9f4-4544-94b2-bf33f827099a","name":"Appendice","slug":"Appendix","availabilityStatus":"NATIONAL"},{"id":"a1a48b7c-8a7c-4db8-92f3-3caf450fc27c","name":"Estomac","slug":"Gastric","availabilityStatus":"NATIONAL"},{"id":"bb7be128-2146-4953-b4c5-c1789a5ec52a","name":"Intestin","slug":"Small bowel","availabilityStatus":"NATIONAL"},{"id":"e88e1a30-6607-43cb-8071-25e3e4b205fe","name":"Pancréas","slug":"Pancreas","availabilityStatus":"NATIONAL"},{"id":"637b9ce7-49bd-4da1-943b-63b9a4efa9be","name":"Péritoine","slug":"Peritoneum","availabilityStatus":"NATIONAL"},{"id":"c848dc1d-9fd8-41d2-899b-62ecfb6f9c24","name":"Rectum","slug":"Rectum","availabilityStatus":"NATIONAL"},{"id":"ba1cf127-4ae9-4e7b-81df-99983e13238f","name":"Voies biliaires","slug":"Bile duct","availabilityStatus":"NATIONAL"}],"histologies":[{"id":"483180e5-b7ca-44b9-a64d-d076ffb278cd","name":"Toutes histologies","slug":"All histologies"}],"specialities":[{"id":"48c78eab-0416-4ced-b901-9de7da518478","name":"Digestif","slug":"Gastrointestinal cancer","availabilityStatus":"NATIONAL"}],"biomarkerAlterations":[{"id":"ba146068-348a-458a-ae5a-db680365f7b4","name":"Non ciblé","slug":"Non ciblé"}]}},{"id":"dda2145b-b481-4ad2-b3cf-be7393fc7f53","name":"EXPÉRIMENTAL : Nal-IRI (Onivyde) - 75 mg/m²","maximumLines":null,"minimumLines":1,"allBiomarkerAlterationRequired":true,"medicalMetadata":{"id":"9c92774d-a1ee-4a2b-8e34-ec5c0f8323ce","phase":"ONE","oms":null,"recistMeasurable":null,"brainMetastasis":"NO","situations":["METASTATIC"],"organs":[{"id":"c20c3e8b-a9f4-4544-94b2-bf33f827099a","name":"Appendice","slug":"Appendix","availabilityStatus":"NATIONAL"},{"id":"a1a48b7c-8a7c-4db8-92f3-3caf450fc27c","name":"Estomac","slug":"Gastric","availabilityStatus":"NATIONAL"},{"id":"bb7be128-2146-4953-b4c5-c1789a5ec52a","name":"Intestin","slug":"Small bowel","availabilityStatus":"NATIONAL"},{"id":"e88e1a30-6607-43cb-8071-25e3e4b205fe","name":"Pancréas","slug":"Pancreas","availabilityStatus":"NATIONAL"},{"id":"637b9ce7-49bd-4da1-943b-63b9a4efa9be","name":"Péritoine","slug":"Peritoneum","availabilityStatus":"NATIONAL"},{"id":"c848dc1d-9fd8-41d2-899b-62ecfb6f9c24","name":"Rectum","slug":"Rectum","availabilityStatus":"NATIONAL"},{"id":"ba1cf127-4ae9-4e7b-81df-99983e13238f","name":"Voies biliaires","slug":"Bile duct","availabilityStatus":"NATIONAL"}],"histologies":[{"id":"483180e5-b7ca-44b9-a64d-d076ffb278cd","name":"Toutes histologies","slug":"All histologies"}],"specialities":[{"id":"48c78eab-0416-4ced-b901-9de7da518478","name":"Digestif","slug":"Gastrointestinal cancer","availabilityStatus":"NATIONAL"}],"biomarkerAlterations":[{"id":"ba146068-348a-458a-ae5a-db680365f7b4","name":"Non ciblé","slug":"Non ciblé"}]}},{"id":"8c38a355-75cb-4930-abfe-bd724a1a648d","name":"EXPÉRIMENTAL : Nal-IRI (Onivyde) - 90 mg/m²","maximumLines":null,"minimumLines":1,"allBiomarkerAlterationRequired":true,"medicalMetadata":{"id":"3a2a7ff1-5b24-4b19-bb63-5dbbf6496ef3","phase":"ONE","oms":null,"recistMeasurable":null,"brainMetastasis":"NO","situations":["METASTATIC"],"organs":[{"id":"c20c3e8b-a9f4-4544-94b2-bf33f827099a","name":"Appendice","slug":"Appendix","availabilityStatus":"NATIONAL"},{"id":"a1a48b7c-8a7c-4db8-92f3-3caf450fc27c","name":"Estomac","slug":"Gastric","availabilityStatus":"NATIONAL"},{"id":"bb7be128-2146-4953-b4c5-c1789a5ec52a","name":"Intestin","slug":"Small bowel","availabilityStatus":"NATIONAL"},{"id":"e88e1a30-6607-43cb-8071-25e3e4b205fe","name":"Pancréas","slug":"Pancreas","availabilityStatus":"NATIONAL"},{"id":"637b9ce7-49bd-4da1-943b-63b9a4efa9be","name":"Péritoine","slug":"Peritoneum","availabilityStatus":"NATIONAL"},{"id":"c848dc1d-9fd8-41d2-899b-62ecfb6f9c24","name":"Rectum","slug":"Rectum","availabilityStatus":"NATIONAL"},{"id":"ba1cf127-4ae9-4e7b-81df-99983e13238f","name":"Voies biliaires","slug":"Bile duct","availabilityStatus":"NATIONAL"}],"histologies":[{"id":"483180e5-b7ca-44b9-a64d-d076ffb278cd","name":"Toutes histologies","slug":"All histologies"}],"specialities":[{"id":"48c78eab-0416-4ced-b901-9de7da518478","name":"Digestif","slug":"Gastrointestinal cancer","availabilityStatus":"NATIONAL"}],"biomarkerAlterations":[{"id":"ba146068-348a-458a-ae5a-db680365f7b4","name":"Non ciblé","slug":"Non ciblé"}]}}],"trialFacilities":[{"id":"bc5a6b87-1738-4dd9-9650-ed7709808cb0","dataIsUpdatedByPartner":false,"partnerships":[],"recruitingStatus":"CLOSED","departments":[],"standardFacility":{"id":"0af192fe-e9e0-4b91-b4ec-fb9e2b48b0e3","name":"University Hospital (UZ) Gent","logoUrl":"https://api-gateway-prod.klineo.com/s3/public/logos/university_hospital_uz_gent_9000.png","isApproved":true,"address":{"street":"Corneel Heymanslaan 10","city":"Gent","zipCode":"9000","formattedAddress":"Corneel Heymanslaan 10, 9000 Gent, Belgium","toReview":false,"region":"Vlaanderen","countryCode":"BE","latitude":51.0243683,"longitude":3.7261567}},"cohortFacilities":[{"status":"CLOSED","cohort":{"id":"c2df321b-db64-4491-a4b0-fb215062aedd","name":"EXPÉRIMENTAL : Nal-IRI (Onivyde) - 30 mg/m²","maximumLines":null,"minimumLines":1,"allBiomarkerAlterationRequired":true}},{"status":"CLOSED","cohort":{"id":"cb85569c-10e1-483c-85a2-660aaf0c5ebc","name":"EXPÉRIMENTAL : Nal-IRI (Onivyde) - 45 mg/m²","maximumLines":null,"minimumLines":1,"allBiomarkerAlterationRequired":true}},{"status":"CLOSED","cohort":{"id":"458e2492-92e1-4b21-a75c-bbb799c14f52","name":"EXPÉRIMENTAL : Nal-IRI (Onivyde) - 60 mg/m²","maximumLines":null,"minimumLines":1,"allBiomarkerAlterationRequired":true}},{"status":"CLOSED","cohort":{"id":"dda2145b-b481-4ad2-b3cf-be7393fc7f53","name":"EXPÉRIMENTAL : Nal-IRI (Onivyde) - 75 mg/m²","maximumLines":null,"minimumLines":1,"allBiomarkerAlterationRequired":true}},{"status":"CLOSED","cohort":{"id":"8c38a355-75cb-4930-abfe-bd724a1a648d","name":"EXPÉRIMENTAL : Nal-IRI (Onivyde) - 90 mg/m²","maximumLines":null,"minimumLines":1,"allBiomarkerAlterationRequired":true}}]}]},"trialExternalId":"NCT05277766"}]] 1b:null 21:[["$","title","0",{"children":"PIPAC-NAL-IRI | Klineo"}],["$","meta","1",{"name":"description","content":"Irinotécan nanoliposomal en aérosol intrapéritonéal (Nal-IRI) dans la carcinose péritonéale due à un cancer gastro-intestinal L'étude PIPAC NAL-IRI est conçue pour examiner la dose maximale tolérée d'irinotécan nanoliposomal (Nal-IRI, Onivyde) administrée avec une chimiothérapie par aérosol intrapér"}],["$","link","2",{"rel":"canonical","href":"https://app.klineo.com/fr/trial/NCT05277766"}],["$","link","3",{"rel":"alternate","hrefLang":"fr","href":"https://app.klineo.com/fr/trial/NCT05277766"}],["$","link","4",{"rel":"alternate","hrefLang":"de","href":"https://app.klineo.com/de/trial/NCT05277766"}],["$","link","5",{"rel":"alternate","hrefLang":"it","href":"https://app.klineo.com/it/trial/NCT05277766"}],["$","link","6",{"rel":"alternate","hrefLang":"en","href":"https://app.klineo.com/en/trial/NCT05277766"}],["$","link","7",{"rel":"alternate","hrefLang":"nl","href":"https://app.klineo.com/nl/trial/NCT05277766"}],["$","meta","8",{"property":"og:title","content":"PIPAC-NAL-IRI | Klineo"}],["$","meta","9",{"property":"og:description","content":"Irinotécan nanoliposomal en aérosol intrapéritonéal (Nal-IRI) dans la carcinose péritonéale due à un cancer gastro-intestinal L'étude PIPAC NAL-IRI est conçue pour examiner la dose maximale tolérée d'irinotécan nanoliposomal (Nal-IRI, Onivyde) administrée avec une chimiothérapie par aérosol intrapér"}],["$","meta","10",{"property":"og:url","content":"https://app.klineo.com/fr/trial/NCT05277766"}],["$","meta","11",{"property":"og:locale","content":"fr_FR"}],["$","meta","12",{"property":"og:locale:alternate","content":"de_DE"}],["$","meta","13",{"property":"og:locale:alternate","content":"it_IT"}],["$","meta","14",{"property":"og:locale:alternate","content":"en_US"}],["$","meta","15",{"property":"og:locale:alternate","content":"nl_NL"}],["$","meta","16",{"property":"og:type","content":"article"}],["$","meta","17",{"name":"twitter:card","content":"summary_large_image"}],["$","meta","18",{"name":"twitter:title","content":"PIPAC-NAL-IRI | Klineo"}],["$","meta","19",{"name":"twitter:description","content":"Irinotécan nanoliposomal en aérosol intrapéritonéal (Nal-IRI) dans la carcinose péritonéale due à un cancer gastro-intestinal L'étude PIPAC NAL-IRI est conçue pour examiner la dose maximale tolérée d'irinotécan nanoliposomal (Nal-IRI, Onivyde) administrée avec une chimiothérapie par aérosol intrapér"}],["$","link","20",{"rel":"icon","href":"/favicon.ico?favicon.1vj0rgv3-qupt.ico","sizes":"32x29","type":"image/x-icon"}],["$","$L2d","21",{}]]